Pitavastatin Calcium/Ezetimibe

匹伐他汀钙/依折麦布

Report date: 2025/07/08 11:48:28

Base Information

Drug NamePitavastatin Calcium/Ezetimibe
Drug Alias Name1PC111
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsNiemann-Pick C1-like protein 1 inhibitorsCholesterol absorption inhibitors
TargetsHMG-CoA reductaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHypercholesterolemiaDyslipidemias
Global Approved IndicationsHypercholesterolemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/09/26
Country/TerritoryTaiwanNew ZealandAustralia +[5] 
CombinationsYes Pitavastatin CalciumEzetimibe
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOrient Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOrient Pharma Co LtdKowa Dental Health Co LtdLepu Pharmaceuticals Tech Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaDyslipidemias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A